Hermes Medical Solution achieves ARTG listing for Hermia in Australia
Stockholm, Sweden – December 9, 2025 – Hermes Medical Solutions, a recognized global leader in molecular imaging and dosimetry software solutions, is proud to announce Hermia has been successfully included in the Australian Register of Therapeutic Goods (ARTG) by the Therapeutic Goods Administration (TGA). This milestone enables the company’s flagship vendor-neutral molecular imaging platform to expand access to Hermia for nuclear medicine, molecular imaging, and theranostics providers across Australia.
Hermia has established itself worldwide* for its robust functionality, supporting a wide range of modalities (PET/CT, SPECT/CT, PET/MR, RTDOSE) and use cases, from routine image viewing and processing to advanced dosimetry and theranostic planning.
With this listing, Australian clinicians can leverage Hermia’s powerful features such as semi-automated organ segmentation, multi-modality image fusion, advanced dosimetry tools (including voxel-based methods), and flexible workflow configurations—functionalities which have recently been enhanced in global releases of the software.
“We are excited to welcome Australia to the growing global community of Hermia users,” said Tom Francke, CEO at Hermes Medical Solutions. “Our mission has always been to deliver vendor-neutral, high-quality molecular imaging software that empowers clinicians and supports personalized, precise patient care. Now that we have listing status on the ARTG, clinicians in Australia can access to these advanced tools, helping to meet growing demand for modern nuclear medicine solutions.”
Hermes Medical Solutions’ mission is to bring powerful molecular imaging tools to market, and with this achievement, we look forward to building a strong presence and relationships in Australia, backed by our expertise and innovation.
*May be subject to regulatory clearance in your market.
About Hermes Medical Solutions
Since its establishment in 1976, in Stockholm, Sweden, Hermes Medical Solutions continuously innovates to enable faster and more personalized diagnosis and therapies in molecular imaging. Hermes Medical Solutions was first to develop SPECT reconstruction software and dual-head whole-body scanning and first to introduce medical image fusion software for combined viewing of images from different scanners. With Hermia, we empower healthcare professionals with state-of-the-art software for all clinical scenarios into ONE vendor-neutral software suite. Combining leadership in innovation for NM/MI software with customer-driven service is our mission and our success lies in our close and longstanding collaboration with our customers to meet their software, support, and service needs. The result is improved quality in patient management and decision support for thousands of healthcare providers and their patients worldwide.
www.hermesmedical.com
Contact
Bridget Watson
Chief Marketing Officer
Hermes Medical Solutions AB (HQ)
Strandbergsgatan 16
112 51 Stockholm, Sweden
Tel: +46 76 076 47 28
bridget.watson@hermesmedical.com